Skip to main content Skip to search
+34 659 496 544

Cáncer de Mama y Ginecológico

Publicaciones

2020

Pérez Ramírez S, del Monte-Millan, M, Lopez-Tarruella, S, Martínez Jáñez N, Marquez-Rodas, I, Lobo Samper F, Izarzugaza Perón Y, Rubio Terres C, Rubio Rodríguez D, Garcia-Saenz, JA, Moreno Antón F, Zamora Auñón P, Arroyo Yustos M, Lara Álvarez MÁ, Ciruelos Gil EM, Manso Sánchez L, Echarri González MJ, Guerra Martínez JA, Jara Sánchez C, Bueno Muiño C, García Adrián S, Carrión Galindo JR, Valentín Maganto V, Martin, M (2020).

Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience.

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 22(5):717-724.
[doi:10.1007/s12094-019-02176-x]
Gavilá J, De La Haba J, Bermejo B, Rodríguez-Lescure Á, Antón A, Ciruelos E, Brunet J, Muñoz-Couselo E, Santisteban M, Rodríguez Sánchez CA, Santaballa A, Sánchez Rovira P, García Sáenz JÁ, Ruiz-Borrego M, Guerrero-Zotano AL, Huerta M, Cotes-Sanchís A, Lao Romera J, Aguirre E, Cortés J, Llombart-Cussac A (2020).

A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 22(3):420-428.
[doi:10.1007/s12094-019-02145-4]
Quintela-Fandino, M, Morales, S, Cortes-Salgado, A, Manso, L, Apala, JV, Muñoz M, Gasol Cudos A, Salla Fortuny J, Gion, M, Lopez-Alonso, A, Cortes, J, Guerra, J, Malon, D, Caleiras, E, Mulero, F, Mouron, S (2020).

Randomized phase 0/I trial of the mitochondrial inhibitor ME-344 or placebo added to bevacizumab in early HER2-negative breast cancer.

CLINICAL CANCER RESEARCH. Article. 26(1):35-45.
[doi:10.1158/1078-0432.CCR-19-2023]

2019

Ciruelos, EM, Diaz, MN, Isla, MD, Lopez, R, Bernabe, R, Gonzalez, E, Cirauqui, B, Coves, J, Morales, S, Arcediano, A, Barneto, I, Cerezuela, P, Illarramendi, JJ, Morales, C, Ponce, S (2019).

Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer.

EUROPEAN JOURNAL OF CANCER CARE. Article. 28(6).
[doi:10.1111/ecc.13164]
Ciruelos, E, Apellániz-Ruiz M, Cantos, B, Martinez-J??ez, N, Bueno-Mui?o, C, Echarri, MJ, Enrech, S, Guerra, JA, Manso, L, Pascual, T, Dominguez, C, Gonzalo, JF, Sanz, JL, Rodriguez-Antona, C, Sepúlveda JM (2019).

A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.

ONCOLOGIST. Article. 24(11):1024-1033.
[doi:10.1634/theoncologist.2017-0664]
Marin-Rubio, JL, Perez-Gomez, E, Fernandez-Piqueras, J, Villa-Morales, M (2019).

S194-P-FADD as a marker of aggressiveness and poor prognosis in human T-cell lymphoblastic lymphoma.

CARCINOGENESIS. Article. 40(10):1260-1268.
[doi:10.1093/carcin/bgz041]
Jimenez-Heffernan, JA, Romero, J, Barcena, C, Cañizal JM (2019).

Cytological features of rosette-forming glioneuronal tumor of the fourth ventricle.

DIAGNOSTIC CYTOPATHOLOGY. Article. 47(10):1082-1085.
[doi:10.1002/dc.24273]
Adamo, B, Bellet, M, Pare, L, Pascual, T, Vidal, M, Pérez Fidalgo JA, Blanch, S, Martinez, N, Murillo, L, Gomez-Pardo, P, Lopez-Gonzalez, A, Amillano, K, Canes, J, Galvan, P, Gonzalez-Farre, B, Gonzalez, X, Villagrasa, P, Ciruelos, E, Prat, A (2019).

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.

BREAST CANCER RESEARCH. Article. 21(1):108-108.
[doi:10.1186/s13058-019-1195-z]
Saura, C, Hlauschek, D, Oliveira, M, Zardavas, D, Jallitsch-Halper, A, de la Peña L, Nuciforo, P, Ballestrero, A, Dubsky, P, Lombard, JM, Vuylsteke, P, Castaneda, CA, Colleoni, M, Santos Borges G, Ciruelos, E, Fornier, M, Boer, K, Bardia, A, Wilson, TR, Stout, TJ, Hsu, JY, Shi, Y, Piccart, M, Gnant, M, Baselga, J, de Azambuja, E (2019).

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

LANCET ONCOLOGY. Article. 20(9):1226-1238.
[doi:10.1016/S1470-2045(19)30334-1]
Huober, J, Holmes, E, Baselga, J, de Azambuja, E, Untch, M, Fumagalli, D, Sarp, S, Lang, I, Smith, I, Boyle, F, Xu, BH, Lecocq, C, Wildiers, H, Jouannaud, C, Hackman, J, Dasappa, L, Ciruelos, E, Toral Pena JC, Adamchuk, H, Hickish, T, de la Pena, L, Jackisch, C, Gelber, RD, Piccart-Gebhart, M, Di Cosimo, S (2019).

Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.

EUROPEAN JOURNAL OF CANCER. Article. 118:169-177.
[doi:10.1016/j.ejca.2019.04.038]
Oliveira, M, Saura, C, Nuciforo, P, Calvo, I, Andersen, J, Passos-Coelho, JL, Gil, MG, Bermejo, B, Patt, DA, Ciruelos, E, de la Peña L, Xu, N, Wongchenko, M, Shi, Z, Singel, SM, Isakoff, SJ (2019).

FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.

ANNALS OF ONCOLOGY. Article. 30(8):1289-1297.
[doi:10.1093/annonc/mdz177]
Ciruelos E, Alba E, López R, Lluch A, Martín M, Arroyo I, Navarro B, Carcedo D, Colomer R, Albanell J (2019).

Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval.

Oncotarget. Article. 10(42):4321-4332.
[doi:10.18632/oncotarget.27039]
Prat, A, Brase, JC, Cheng, Y, Nuciforo, P, Pare, L, Pascual, T, Martinez, D, Galvan, P, Vidal, M, Adamo, B, Hortobagyi, GN, Baselga, J, Ciruelos, E (2019).

Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.

ONCOLOGIST. Article. 24(7):893-900.
[doi:10.1634/theoncologist.2018-0407]
Ciruelos E, Pérez-García JM, Gavilá J, Rodríguez A, de la Haba-Rodriguez J (2019).

Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept.

CLINICAL DRUG INVESTIGATION. Review. 39(7):595-606.
[doi:10.1007/s40261-019-00790-9]
Lago, V, Fotopoulou, C, Chiantera, V, Minig, L, Gil-Moreno, A, Cascales-Campos, PA, Jurado, M, Tejerizo, A, Padilla-Iserte, P, Malune, ME, Di Donna, MC, Marina, T, Sanchez-Iglesias, JL, Olloqui, A, Garcia-Granero, A, Matute, L, Fornes, V, Domingo, S (2019).

Risk factors for anastomotic leakage after colorectal resection in ovarian cancer surgery: A multi-centre study.

GYNECOLOGIC ONCOLOGY. Article. 153(3):549-554.
[doi:10.1016/j.ygyno.2019.03.241]
Méndez-Líter JA, Tundidor, I, Nieto-Dominguez, M, de Toro, BF, González Santana A, de Eugenio, LI, Prieto, A, Asensio, JL, Cañada FJ, Sanchez, C, Martinez, MJ (2019).

Transglycosylation products generated by Talaromyces amestolkiae GH3 ß-glucosidases: effect of hydroxytyrosol, vanillin and its glucosides on breast cancer cells.

MICROBIAL CELL FACTORIES. Article. 18(1):97-97.
[doi:10.1186/s12934-019-1147-4]
Andre, F, Ciruelos, E, Rubovszky, G, Campone, M, Loibl, S, Rugo, HS, Iwata, H, Conte, P, Mayer, IA, Kaufman, B, Yamashita, T, Lu, YS, Inoue, K, Takahashi, M, Papai, Z, Longin, AS, Mills, D, Wilke, C, Hirawat, S, Juric, D, SOLAR-1 Study Group (2019).

Alpelisib for PIK3CA -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

NEW ENGLAND JOURNAL OF MEDICINE. Article. 380(20):1929-1940.
[doi:10.1056/NEJMoa1813904]
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D (2019).

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

ANNALS OF ONCOLOGY. Article. 30(5):766-773.
[doi:10.1093/annonc/mdz061]
Sanchez-Rovira, P, Zamora, P, Salvador-Bofill, J, Morales, S, Martinez-Janez, N, Martinez-de-Duenas, E, Lluch, A, Illarramendi, JJ, Gomez-Pardo, P, Gavilá Gregori J, Garcia-Palomo, A, Garcia-Mata, J, Fernandez, Y, del Barco, S, de Juan, A, Ciruelos, E, Chacon, JI, Calvo, L, Barnadas, A, Albanell, J (2019).

Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists.

Journal Of Drug Assessment. Article. 8(1):62-69.
[doi:10.1080/21556660.2019.1604375]
Manso, L, Moreno Anton F, Izarzugaza Peron Y, Delgado Mingorance JI, Borrega Garcia P, Echarri Gonzalez MJ, Martinez-Janez, N, Lopez-Gonzalez, A, Olier Garate C, Ballesteros Garcia A, Chacon Lopez-Muniz I, Ciruelos Gil E, Garcia-Saenz, JA, Paz-Ares, L (2019).

Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study

Breast Journal. Article. 25(2):219-225.
[doi:10.1111/tbj.13199]
Blasco-Benito, S, Moreno, E, Seijo-Vila, M, Tundidor, I, Andradas, C, Caffarel, MM, Caro-Villalobos, M, Uriguen, L, Diez-Alarcia, R, Moreno-Bueno, G, Hernandez, L, Manso, L, Homar-Ruano, P, McCormick, PJ, Bibic, L, Bernado-Morales, C, Arribas, J, Canals, M, Casado, V, Canela, EI, Guzman, M, Perez-Gomez, E, Sanchez, C (2019).

Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. Article. 116(9):3863-3872.
[doi:10.1073/pnas.1815034116]
Gonzalez-Rincon, J, Mendez, M, Gomez, S, Garcia, JF, Martin, P, Bellas, C, Pedrosa, L, Rodriguez-Pinilla, SM, Camacho, FI, Quero, C, Perez-Callejo, D, Rueda, A, Llanos, M, Gomez-Codina, J, Piris, MA, Montes-Moreno, S, Barcena, C, Rodriguez-Abreu, D, Menarguez, J, De la Cruz-Merino, L, Monsalvo, S, Parejo, C, Royuela, A, Kwee, I, Cascione, L, Arribas, A, Bertoni, F, Mollejo, M, Provencio, M, Sanchez-Beato, M (2019).

Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma

PLOS ONE. Article. 14(2).
[doi:10.1371/journal.pone.0212813]
Page, A, Ortega, A, Alameda, JP, Navarro, M, Paramio, JM, Saiz-Pardo, M, Almeida, EI, Hernandez, P, Fernandez-Acenero, MJ, Garcia-Fernandez, RA, Casanova, ML (2019).

IKKa Promotes the Progression and Metastasis of Non-Small Cell Lung Cancer Independently of its Subcellular Localization.

Computational and Structural Biotechnology Journal. Article. 17:251-262.
[doi:10.1016/j.csbj.2019.02.003]
Perez-Fidalgo, JA, Iglesias, M, Bohn, U, Calvo E, Garcia, Y, Guerra, E, Manso, L, Santaballa, A, Gonzalez-Martin, A (2019).

GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer

Future Science Oa. Article. 5(2).
[doi:10.4155/fsoa-2018-0107]
Cristofanilli, M, Pierga, JY, Reuben, J, Rademaker, A, Davis, AA, Peeters, DJ, Fehm, T, Nole, F, Gisbert-Criado, R, Mavroudis, D, Grisanti, S, Giuliano, M, Garcia-Saenz, JA, Stebbing, J, Caldas, C, Gazzaniga, P, Manso, L, Zamarchi, R, de Lascoiti, AF, de Mattos-Arruda, L, Ignatiadis, M, Cabel, L, van Laere, SJ, Meier-Stiegen, F, Sandri, MT, Vidal-Martinez, J, Politaki, E, Consoli, F, Generali, D, Cappelletti, MR, Diaz-Rubio, E, Krell, J, Dawson, SJ, Raimondi, C, Rutten, A, Janni, W, Munzone, E, Caranana, V, Agelaki, S, Almici, C, Dirix, L, Solomayer, EF, Zorzino, L, Darrigues, L, Reis, JS, Gerratana, L, Michiels, S, Bidard, FC, Pantel, K (2019).

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. Review. 134:39-45.
[doi:10.1016/j.critrevonc.2018.12.004]
Rojas, LK, Trilla-Fuertesr, L, Gamez-Pozo, A, Chiva, C, Sepulveda, J, Manso, L, Prado-Vazquez, G, Zapater-Moros, A, Lopez-Vacas, R, Ferrer-Gomez, M, Mendiola, C, Espinosa, E, Sabido, E, Ciruelos, E, Vara JAF (2019).

Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer

Ecancermedicalscience. Article. 13:891-891.
[doi:10.3332/ecancer.2019.891]
Alameda, JP, Ramirez, A, Garcia-Fernandez, RA, Navarro, M, Page, A, Segovia, JC, Sanchez, R, Suarez-Cabrera, C, Paramio, JM, Bravo, A, Fernandez-Acenero, MJ, Casanova, ML (2019).

Premature aging and cancer development in transgenic mice lacking functional CYLD

Aging-Us. Article. 11(1):127-159.
[doi:10.18632/aging.101732]
Gavila, J, Oliveira, M, Pascual, T, Perez-Garcia, J, Gonzalez, X, Canes, J, Pare, L, Calvo, I, Ciruelos, E, Munoz, M, Virizuela, JA, Ruiz, I, Andres, R, Perello, A, Martinez, J, Morales, S, Marin-Aguilera, M, Martinez, D, Quero, JC, Llombart-Cussac, A, Prat, A (2019).

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

BMC MEDICINE. Article. 17(1):8-8.
[doi:10.1186/s12916-018-1233-1]
Ayala de la Peña F, Andrés R, Garcia-Sáenz JA, Manso L, Margelí M, Dalmau E, Pernas S, Prat A, Servitja S, Ciruelos E (2019).

SEOM clinical guidelines in early stage breast cancer (2018)

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 21(1):18-30.
[doi:10.1007/s12094-018-1973-6]

2018

Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S, EORTC, MRC CHORUS study investigators (2018).

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

LANCET ONCOLOGY. Article. 19(12):1680-1687.
[doi:10.1016/S1470-2045(18)30566-7]
Blancas, I, Fontanillas, M, Conde, V, Lao, J, Martinez, E, Sotelo, MJ, Jaen, A, Bayo, JL, Carabantes, F, Illarramendi, JJ, Gordon, MM, Cruz, J, Garcia-Palomo, A, Mendiola, C, Perez-Ruiz, E, Bofill, JS, Baena-Canada, JM, Janez, NM, Esquerdo, G, Ruiz-Borrego, M (2018).

Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice (vol 20, pg 862, 2018)

CLINICAL & TRANSLATIONAL ONCOLOGY. Correction. 20(12):1631-1632.
[doi:10.1007/s12094-018-1956-7]
Blasco-Benito, S, Seijo-Vila, M, Caro-Villalobos, M, Tundidor, I, Andradas, C, Garcia-Taboada, E, Wade, J, Smith, S, Guzman, M, Perez-Gomez, E, Gordon, M, Sanchez, C (2018).

Appraising the "entourage effect": Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer

BIOCHEMICAL PHARMACOLOGY. Article. 157:285-293.
[doi:10.1016/j.bcp.2018.06.025]
Minig, L, Cabrera, S, Oliver, R, Couso, A, Rubio, MJ, Iacoponi, S, Martin-Salamanca, MB, Carballo-Rastrilla, S, Cadenas-Rebollo, JM, Garcia-Garcia, A, Gil-Ibanez, B, Juan-Fita, MJ, Patrono, MG (2018).

Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 20(10):1337-1344.
[doi:10.1007/s12094-018-1865-9]
Jiménez-Heffernan JA, Bárcena C, Muñoz-Hernández P (2018).

Cytological features of breast peri-implant papillary synovial metaplasia

DIAGNOSTIC CYTOPATHOLOGY. Article. 46(9):769-771.
[doi:10.1002/dc.23947]
Vergote, I, von Moos, R, Manso, L, Van Nieuwenhuysen, E, Concin, N, Sessa, C (2018).

Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study

GYNECOLOGIC ONCOLOGY. Article. 150(3):471-477.
[doi:10.1016/j.ygyno.2018.07.018]
Zagorac, I, Fernandez-Gaitero, S, Penning, R, Post, H, Bueno, MJ, Mouron, S, Manso, L, Morente, MM, Alonso, S, Serra, V, Munoz, J, Gomez-Lopez, G, Lopez-Acosta, JF, Jimenez-Renard, V, Gris-Oliver, A, Al-Shahrour, F, Pineiro-Yanez, E, Montoya-Suarez, JL, Apala, JV, Moreno-Torres, A, Colomer, R, Dopazo, A, Heck AJR, Altelaar, M, Quintela-Fandino, M (2018).

In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer

NATURE COMMUNICATIONS. Article. 9(1):3501-3501.
[doi:10.1038/s41467-018-05742-z]
Colomer R, Aranda-Lopez I, Albanell J, Garcia-Caballero T, Ciruelos E, Lopez-Garcia MA, Cortes J, Rojo F, Martin M, Palacios-Calvo J (2018).

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology (vol 20, pg 815, 2018)

CLINICAL & TRANSLATIONAL ONCOLOGY. Correction. 20(8):1093-1095.
[doi:10.1007/s12094-018-1909-1]
Pernaut, C, Lopez, F, Ciruelos, E (2018).

Standard Neoadjuvant Treatment in Early/Locally Advanced Breast Cancer

Breast Care. Review. 13(4):244-249.
[doi:10.1159/000491759]
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I, Gomez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM, SOFT and TEXT Investigators and the International Breast Cancer Study Group (2018).

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

NEW ENGLAND JOURNAL OF MEDICINE. Article. 379(2):122-137.
[doi:10.1056/NEJMoa1803164]
Colomer, R, Aranda-Lopez, I, Albanell, J, Garcia-Caballero, T, Ciruelos, E, Lopez-Garcia, MA, Cortes, J, Rojo, F, Martin, M, Palacios-Calvo, J (2018).

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

CLINICAL & TRANSLATIONAL ONCOLOGY. Review. 20(7):815-826.
[doi:10.1007/s12094-017-1800-5]
Blancas, I, Fontanillas, M, Conde, V, Lao, J, Martinez, E, Sotelo, MJ, Jaen, A, Bayo, JL, Carabantes, F, Illarramendi, JJ, Gordon, MM, Cruz, J, Garcia-Palomo, A, Mendiola, C, Perez-Ruiz, E, Bofill, JS, Baena-Canada, JM, Janez, NM, Esquerdo, G, Ruiz-Borrego, M (2018).

Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 20(7):862-869.
[doi:10.1007/s12094-017-1797-9]
Ciruelos, E, Vidal, M, Martínez de Dueñas E, Martinez-Janez, N, Fernandez, Y, Garcia-Saenz, J, Murillo, L, Carabantes, F, Beliera, A, Fonseca, R, Gavila, J (2018).

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain

CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 20(6):753-760.
[doi:10.1007/s12094-017-1784-1]
Carretero-Gonzalez, A, Otero, I, Carril-Ajuria, L, de Velasco, G, Manso, L (2018).

Exosomes: Definition, Role in Tumor Development and Clinical Implications

CANCER MICROENVIRONMENT. Review. 11(1):13-21.
[doi:10.1007/s12307-018-0211-7]
Pernas, S, Martin, M, Kaufman, PA, Gil-Martin, M, Gomez Pardo P, Lopez-Tarruella, S, Manso, L, Ciruelos, E, Perez-Fidalgo, JA, Hernando, C, Ademuyiwa, FO, Weilbaecher, K, Mayer, I, Pluard, TJ, Martinez Garcia M, Vahdat, L, Perez-Garcia, J, Wach, A, Barker, D, Fung, S, Romagnoli, B, Cortes, J (2018).

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial

LANCET ONCOLOGY. Article. 19(6):812-824.
[doi:10.1016/S1470-2045(18)30147-5]
Selle, F, Colombo, N, Korach, J, Mendiola, C, Cardona, A, Ghazi, Y, Oza, AM (2018).

Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Article. 28(4):729-737.
[doi:10.1097/IGC.0000000000001221]
Oskay-Özcelik G, Alavi S, Richter R, Keller M, Cecere SC, Cormio G, Joly F, Kurtz JE, du Bois A, Maciejewski M, Jedryka M, Vergote I, Van Nieuwenhuysen E, Casado A, Mendiola C, Achimas-Cadariu P, Vlad C, Reimer D, Zeimet AG, Friedlander M, Sehouli J (2018).

Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries.

ANNALS OF ONCOLOGY. Article. 29(4):910-916.
[doi:10.1093/annonc/mdy037]
Kaufman, PA, Pernas, S, Martin, M, Gil-Martin, M, Pardo, PG, Sara, LT, Manso, L, Ciruelos, E, Perez-Fidalgo, JA, Hernando, C, Ademuyiwa, FO, Weilbaecher, K, Mayer, I, Pluard, TJ, Garcia, MM, Vahdat, L, Wach, A, Barker, D, Romagnoli, B, Cortes, J (2018).

Balixafortide (a CXCR4 antagonist) plus eribulin in HER2-negative metastatic breast cancer (MBC): A Phase I open-label trial

EUROPEAN JOURNAL OF CANCER. Meeting Abstract. 92:117-118.
Prat, A, Brase, JC, Cheng, Y, Nuciforo, P, Pare, L, Pascual, T, Martinez, D, Galvan, P, Vidal, M, Adamo, B, Hortobagyi, G, Baselga, J, Ciruelos, E (2018).

PAM50 intrinsic subtype in hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial

EUROPEAN JOURNAL OF CANCER. Meeting Abstract. 92:117-117.
[doi:10.1016/S0959-8049(18)30574-4]
Cala, MP, Agullo-Ortuno, MT, Prieto-Garcia, E, Gonzalez-Riano, C, Parrilla-Rubio, L, Barbas, C, Diaz-Garcia, CV, Garcia, A, Pernaut, C, Adeva, J, Riesco, MC, Ruperez, FJ, Lopez-Martin, JA (2018).

Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE. Article. 9(2):348-357.
[doi:10.1002/jcsm.12270]
Brandariz L, Arriba M, García JL, Cano JM, Rueda D, Rubio E, Rodríguez Y, Pérez J, Vivas A, Sánchez C, Tapial S, Pena L, García-Arranz M, García-Olmo D, Urioste M, González-Sarmiento R, Perea J (2018).

Differential clinicopathological and molecular features within late-onset colorectal cancer according to tumor location.

Oncotarget. Article. 9(20):15302-15311.
[doi:10.18632/oncotarget.24502]
Garrido, ML, Morago, AJ, Rovira, PS, Olarte, PE, Sanchez, CP, Sanchez, LM (2018).

Experience with eribulin in the treatment of elderly women with metastatic breast cancer:case studies

FUTURE ONCOLOGY. Article. 14(7):21-27.
[doi:10.2217/fon-2017-0357]
Ciruelos, E, Villagrasa, P, Pare, L, Oliveira, M, de la Pena, L, Pernas, S, Cortes, J, Soberino, J, Adamo, B, Vazquez, S, Martinez, N, Perello, A, Bermejo, B, Martinez, E, Garau, I, Mele, M, Morales, S, Galvan, P, Pascual, T, Nuciforo, P, Gonzalez, X, Prat, A (2018).

PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial

CANCER RESEARCH. Meeting Abstract. 78(4).
Smyth, LM, Oliveira, M, Ciruelos, E, Tamura, K, El-Khoueiry, A, Mita, A, You, B, Renouf, DJ, Sablin, MP, Lluch, A, Mayer, IA, Bando, H, Yamashita, H, Ambrose, H, de Bruin, E, Carr, TH, Corcoran, C, Foxley, A, Lindemann, JPO, Maudsley, R, Pass, M, Rutkowski, A, Schiavon, G, Banerji, U, Scaltriti, M, Taylor, BS, Chandarlapaty, S, Baselga, J, Hyman, DM (2018).

AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer

CANCER RESEARCH. Meeting Abstract. 78(4).
Gavila, J, Oliveira, M, Pascual, T, Perez, J, Canes, J, Gonzalez, X, Pare, L, Calvo, I, Ciruelos, E, Munoz, M, Virizuela, JA, Ruiz, I, Andres, R, Perello, A, Martinez, J, Morales, S, Marin, M, Martinez, D, Quero, JC, Llombart-Cussac, A, Prat, A (2018).

Association of intrinsic subtype and immune genes with pathological complete response in the OPTIHER-HEART phase II clinical trial following neoadjuvant trastuzumab/pertuzumab-based chemotherapy in HER2-positive breast cancer

CANCER RESEARCH. Meeting Abstract. 78(4).
Cortes, A, Apala, JV, Malon, D, Guerra, J, Gion-Cortes, M, Manso, L, Hornedo, J, Gonzalez-Cortijo, L, Mouron, S, Quintela-Fandino, M (2018).

CNIO-BR-009 trial: Targeting mitochondrial metabolism with ME-344 in breast cancer upon bevacizumab-induced vascular normalization: A phase 0 randomized clinical trial

CANCER RESEARCH. Meeting Abstract. 78(4).
de Azambuja, E, Saura, C, Nuciforo, P, Frantal, S, Oliveira, M, Zardavas, D, Jallitsch-Halper, A, de la Pena, L, Dubsky, P, Lombard, JM, Vuylsteke, P, Altamirano, CC, Sanchez, C, Ballestrero, A, Colleoni, M, Borges, GS, Ciruelos, E, Bardia, A, Fornier, M, Boer, K, Wilson, TR, Stout, TJ, Hsu, JY, Shi, Y, Piccart, M, Baselga, J, Gnant, M (2018).

Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer

CANCER RESEARCH. Meeting Abstract. 78(4).
Nuciforo, P, Holgado, E, Llombart, A, Fasani, R, Pare, L, Pascual, T, Oliveira, M, Martinez, N, Bermejo, B, Vidal, M, Pernas, S, Lopez, R, Munoz, M, Garau, I, Manso, L, Alarcon, J, Martinez, E, Villagrasa, P, Cortes, J, Prat, A (2018).

A predictive model of pathological response following dual HER2 blockade-only based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer

CANCER RESEARCH. Meeting Abstract. 78(4).
Gil-Gil, M, Bellet, M, Morales, S, Barnadas, A, Manso, L, Ruiz, IM, Azaro, A, Gil, EC, Martinez, EG, Marinez, N, Mele, M, Soler, T, Villagrasa, P, Pernas, S (2018).

SOLTI-0702 CAPRICE: Final results of a phase II study of pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as neoadjuvant chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: 5-year overall survival disease free survival and late cardiac safety

CANCER RESEARCH. Meeting Abstract. 78(4).
Leo, AD, Toi, M, Campone, M, Sohn, JH, Shimon, SP, Huober, J, Park, IH, Tredan, O, Chen, SC, Manso, L, Freedman, O, Jaliffe, GG, Forrester, TD, Frenzel, M, Barriga, S, Smith, IC, Bourayou, N, Goetz, MP (2018).

MONARCH 3: Abemaciclib as Initial Therapy for Patients with HR+/HER2-Advanced Breast Cancer

ONCOLOGY RESEARCH AND TREATMENT. Meeting Abstract. 41:5-5.
Manso, L, Sanchez-Munoz, A, Calvo, I, Izarzugaza, Y, Plata, J, Rodriguez, C (2018).

Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer

Breast Care. Review. 13(4):277-283.
[doi:10.1159/000488794]
Redondo, A, Ramos Vazquez M, Manso, L, Gil, MJG, Garau Llinas I, Garcia-Garre, E, Rodriguez, CA, Chacon, JI, Lopez-Vivanco, G (2018).

Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study

ONCOTARGETS AND THERAPY. Article. 11:5845-5852.
[doi:10.2147/OTT.S170303]
Di Leo, A, Johnston, S, Lee, KS, Ciruelos, E, Lønning PE, Janni, W, O'Regan, R, Mouret-Reynier, MA, Kalev, D, Egle, D, Csoszi, T, Bordonaro, R, Decker, T, Tjan-Heijnen VCG, Blau, S, Schirone, A, Weber, D, El-Hashimy, M, Dharan, B, Sellami, D, Bachelot, T (2018).

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

LANCET ONCOLOGY. Article. 19(1):87-100.
[doi:10.1016/S1470-2045(17)30688-5]
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, Panel Members of the St Gallen International Expert Consensus on the Primary The, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B (2018).

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

ANNALS OF ONCOLOGY. Letter. 29(1):281-282.
[doi:10.1093/annonc/mdx543]
Nuciforo, P, Pascual, T, Cortes, J, Llombart-Cussac, A, Fasani, R, Pare, L, Oliveira, M, Galvan, P, Martinez, N, Bermejo, B, Vidal, M, Pernas, S, Lopez, R, Muñoz M, Garau, I, Manso, L, Alarcon, J, Martinez, E, Rodrik-Outmezguine, V, Brase, JC, Villagrasa, P, Prat, A, Holgado, E (2018).

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

ANNALS OF ONCOLOGY. Article. 29(1):170-177.
[doi:10.1093/annonc/mdx647]

2017

Page A, Navarro M, Suárez-Cabrera C, Bravo A, Ramirez A (2017).

Context-Dependent Role of IKKß in Cancer.

Genes. Article. 8(12).
[doi:10.3390/genes8120376]
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A (2017).

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

JOURNAL OF CLINICAL ONCOLOGY. Article. 35(32):3638-3646.
[doi:10.1200/JCO.2017.75.6155]
Díaz-Alonso J, de Salas-Quiroga A, Paraíso-Luna J, García-Rincón D, Garcez PP, Parsons M, Andradas C, Sánchez C, Guillemot F, Guzmán M, Galve-Roperh I (2017).

Loss of Cannabinoid CB1 Receptors Induces Cortical Migration; Malformations and Increases Seizure Susceptibility

CEREBRAL CORTEX. Article. 27(11):5303-5317.
[doi:10.1093/cercor/bhw309]
Pont LP, Marcelli S, Robustillo M, Song D, Grandes D, Martin M, Iglesias I, Aso J, Laloumet I, Díaz AJ (2017).

Immediate Breast Reconstruction with Abdominal Free Flap and Adjuvant; Radiotherapy: Evaluation of Quality of Life and Outcomes

PLASTIC AND RECONSTRUCTIVE SURGERY. Article. 140(4):681-690.
[doi:10.1097/PRS.0000000000003664]
Oliver-Pérez MLR, Bravo Violeta V, Legorburu Alonso B, Betancor Pérez D, Bebia Conesa V, Jiménez López JS (2017).

Incidence of Anal Dysplasia in a Population of High-Risk Women:; Observations at a Cervical Pathology Unit

JOURNAL OF LOWER GENITAL TRACT DISEASE. Article. 21(4):329-335.
[doi:10.1097/LGT.0000000000000328]
Page A, Bravo A, Suarez-Cabrera C, Alameda JP, Casanova ML, Lorz C, Segrelles C, Segovia JC, Paramio JM, Navarro M, Ramirez A (2017).

IKK beta-Mediated Resistance to Skin Cancer Development Is; Ink4a/Arf-Dependent

MOLECULAR CANCER RESEARCH. Article. 15(9):1255-1264.
[doi:10.1158/1541-7786.MCR-17-0157]
Gamez-Pozo, A, Trilla-Fuertes, L, Berges-Soria, J, Selevsek, N, Lopez-Vacas, R, Diaz-Almiron, M, Nanni, P, Arevalillo, JM, Navarro, H, Grossmann, J, Moreno, FG, Rioja, RG, Prado-Vazquez, G, Zapater-Moros, A, Main, P, Feliu, J, del Prado, PM, Zamora, P, Ciruelos, E, Espinosa, E, Vara, JAF (2017).

Functional proteomics outlines the complexity of breast cancer molecular; subtypes

SCIENTIFIC REPORTS. Article. 7(1):10100-10100.
[doi:10.1038/s41598-017-10493-w]
Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, St. Gallen International Expert Consensus on the Primary Therapy of Early Breast, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B (2017).

De-escalating and escalating treatments for early-stage breast cancer:; the St. Gallen International Expert Consensus Conference on the Primary; Therapy of Early Breast Cancer 2017

ANNALS OF ONCOLOGY. Article. 28(8):1700-1712.
[doi:10.1093/annonc/mdx308]
Villalaín-González C, Tejerizo-García Á, Lopez-Garcia P, López-González G, Oliver-Perez MR, Jiménez-López JS (2017).

Vaginal metastasis as the initial presentation of leiomyosarcoma: a case; report

BMC CANCER. Article. 17(1):503-503.
[doi:10.1186/s12885-017-3484-1]
Pascual, T, Apellaniz-Ruiz, M, Pernaut, C, Cueto-Felgueroso, C, Villalba, P, Alvarez, C, Manso, L, Inglada-Perez, L, Robledo, M, Rodriguez-Antona, C, Ciruelos, E (2017).

Polymorphisms associated with everolimus pharmacokinetics, toxicity and; survival in metastatic breast cancer

PLOS ONE. Article. 12(7).
[doi:10.1371/journal.pone.0180192]
Simón E, Tejerizo Á, Muñoz JL, Álvarez C, Marqueta L, Jiménez JS (2017).

Conservative management in ureteric hydronephrosis due to deep; endometriosis: Could the levonorgestrel-intrauterine device be an; option?

JOURNAL OF OBSTETRICS AND GYNAECOLOGY. Article. 37(5):639-644.
[doi:10.1080/01443615.2017.1286467]
Gámez-Pozo A, Trilla-Fuertes L, Prado-Vázquez G, Chiva C, López-Vacas R, Nanni P, Berges-Soria J, Grossmann J, Díaz-Almirón M, Ciruelos E, Sabidó E, Espinosa E, Fresno Vara JÁ (2017).

Prediction of adjuvant chemotherapy response in triple negative breast; cancer with discovery and targeted proteomics

PLOS ONE. Article. 12(6).
[doi:10.1371/journal.pone.0178296]
Rynne-Vidal A, Au-Yeung CL, Jiménez-Heffernan JA, Pérez-Lozano ML, Cremades-Jimeno L, Bárcena C, Cristóbal-García I, Fernández-Chacón C, Yeung TL, Mok SC, Sandoval P, López-Cabrera M (2017).

Mesothelial-to-mesenchymal transition as a possible therapeutic target; in peritoneal metastasis of ovarian cancer

JOURNAL OF PATHOLOGY. Article. 242(2):140-151.
[doi:10.1002/path.4889]
Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS (2017).

A phase II study of combined ridaforolimus and dalotuzumab compared with; exemestane in patients with estrogen receptor-positive breast cancer

BREAST CANCER RESEARCH AND TREATMENT. Article. 163(3):535-544.
[doi:10.1007/s10549-017-4199-3]
Alkatout I, Hübner F, Wenners A, Hedderich J, Wiedermann M, Sánchez C, Röcken C, Mathiak M, Maass N, Klapper W (2017).

In situ localization of tumor cells associated with the; epithelial-mesenchymal transition marker Snail and the prognostic impact; of lymphocytes in the tumor microenvironment in invasive ductal breast; cancer

EXPERIMENTAL AND MOLECULAR PATHOLOGY. Article. 102(2):268-275.
[doi:10.1016/j.yexmp.2017.02.013]
Jiménez-Heffernan JA, Freih Fraih A, Álvarez F, Bárcena C, Corbacho C (2017).

Cytologic Features of Pleomorphic Xanthoastrocytoma, WHO Grade II. A; Comparative Study with Glioblastoma

DIAGNOSTIC CYTOPATHOLOGY. Article. 45(4):339-344.
[doi:10.1002/dc.23660]
Fernandez-Martinez A, Pascual T, Perrone G, Morales S, de la Haba J, González-Rivera M, Galván P, Zalfa F, Amato M, Gonzalez L, Prats M, Rojo F, Manso L, Paré L, Alonso I, Albanell J, Vivancos A, González A, Matito J, González S, Fernandez P, Adamo B, Muñoz M, Viladot M, Font C, Aya F, Vidal M, Caballero R, Carrasco E, Altomare V, Tonini G, Prat A, Martin M (2017).

Limitations in predicting PAM50 intrinsic subtype and risk of relapse; score with Ki67 in estrogen receptor-positive HER2-negative breast; cancer

Oncotarget. Article. 8(13):21930-21937.
[doi:10.18632/oncotarget.15748]
Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Mouron S, Guerra J, Bermejo B, Zamora E, García-Saenz JA, Simon SP, Carrasco E, Escudero MJ, Campo R, Colomer R, Blasco MA (2017).

Critically short telomeres and toxicity of chemotherapy in early breast; cancer

Oncotarget. Article. 8(13):21472-21482.
[doi:10.18632/oncotarget.15592]
Page A, Navarro M, Suarez-Cabrera C, Alameda JP, Casanova ML, Paramio JM, Bravo A, Ramirez A (2017).

Protective role of p53 in skin cancer: Carcinogenesis studies in mice; lacking epidermal p53 (vol 7, pg 20902, 2016)

Oncotarget. Correction. 8(13):22304-22304.
[doi:10.18632/oncotarget.16592]
Suárez-Cabrera C, Quintana RM, Bravo A, Casanova ML, Page A, Alameda JP, Paramio JM, Maroto A, Salamanca J, Dupuy AJ, Ramírez A, Navarro M (2017).

A Transposon-based Analysis Reveals RASA1 Is Involved in Triple-Negative Breast Cancer

CANCER RESEARCH. Article. 77(6):1357-1368.
[doi:10.1158/0008-5472.CAN-16-1586]
Di Leo, A., Lee, K. Seok, Ciruelos, E., Lonning, P., Janni, W., O'Regan, R., Reynier, M-A Mouret, Kalev, D., Egle, D., Csoszi, T., Bordonaro, R., Decker, T., Tjan-Heijnen, V. C., Blau, S., Schirone, A., Weber, D., El-Hashimy, M., Dharan, B., Sellami, D., Bachelot, T. (2017).

BELLE-3: A phase III study of buparlisib plus fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-S4-07]
Pascual, T., Gamez-Pozo, A., Camara-Jurado, M., Manso, L. M., Perez-Campos, A., Trilla, L., Fresno-Vara, J. A., Ciruelos, E. M. (2017).

Differential expression of microRNAs (miRNAs) in HER2 negative breast cancer (BC)

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P4-07-09]
Martin, M., Kahan, Z., Carrasco, E., Bartlett, C. H., Casas, M., Gil-Gil, M., Munoz, M., Ciruelos, E. M., Ruiz-Borrego, M., Margeli, M., Anton, A., Bermejo, B., Morales, S., Gal-Yam, E., Koehler, M., Garcia-Saenz, J. A., de la Haba, J., Chacon, I., Zielinski, C. (2017).

Phase III study of palbociclib (PD-0332991) in combination with endocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. ``The PEARL study'' (GEICAM/2013-02)

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-OT2-01-06]
Manso Sanchez, L., Moreno Anton, F., Izarzugaza Peron, Y., Delgado Mingorance, I., Borrega Garcia, P., Echarri Gonzalez, M. J., Martinez Janez, N., Lopez Gonzalez, A., Olier Garate, C., Ballesteros Garcia, A., Chacon Lopez-Muniz, I., Ciruelos Gil, E. M., Garcia Saenz, J. A., Paz-Ares Rodriguez, L. (2017).

High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with eribulin as third line chemotherapy (ONSITE study)

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P6-07-21]
Gavila, J., Perez-Garcia, J., Calvo, I., Ciruelos, E., Munoz, M., Virizuela, J. A., Ruiz, I., Andres, R., Morales, S., Perello, A., Sanchez, P., Garcia-Saenz, J. A., Quero Guillen, J. C., Gonzalez-Santiago, S., Garau Llinas, I., Gonzalez-Martin, A., Sanchez de Ibarguen, B. Cantos, Zaragoza, K., de la Pena, L., Llombart-Cussac, A., Oliveira, M. (2017).

Neoadjuvant non-pegylated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2+breast cancer - Final results of the SOLTI OPTI-HER HEART study

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P4-21-05]
Ciruelos, E. M., Montano, A., Rodriguez, C. A., Gonzalez-Flores, E., Lluch, A., Garrigos, L., Quiroga, V., Anton, A., Malon, D., Chacon, J. I., Velasco, M., Gonzalez-Cortijo, L., Jolis, L., Pascual, T., Amigo, Y., Casas, M., Camara, M. C., Carrasco, E., Casas, A. (2017).

Phase III trial to evaluate patient's preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GEICAM/2012-07)

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P4-21-16]
Colomer, R., Ciruelos, E., De la Haba, J., Martin, M., De Salas-Cansado, M., Munoz-Molina, B., Albanell, J. (2017).

Estimating costs of relapsing HER2+breast cancer in Spain

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P3-12-05]
Bachelot, T., Puglisi, F., Ciruelos, E., Peretz-Yablonski, T., Schneeweiss, A., Easton, V., Lindegger, N., Restuccia, E., Miles, D. (2017).

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (PERUSE)

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P4-21-04]
Andre, F., Kaufman, B., Juric, D., Ciruelos, E. M., Iwata, H., Mayer, I. A., Rugo, H. S., Conte, P., Liobl, S., Rubovszky, G., Inoue, K., Tesch, H., Lu, Y-S, Ryvo, L., Longin, A-S, Mills, D., Wilke, C., Germa, C., Campone, M. (2017).

SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-OT2-01-04]
Adamo, B., Vidal, M., Gomez Pardo, P., Zaragoza, K., Ciruelos, E., Virizuela, J. A., Blanch Tormo, S., Perez-Fidalgo, J. A., Murillo, L., Lopez-Gonzalez, A., Amillano Parraga, K., Martinez Janez, N., Gonzalez Farre, X., Prat, A. (2017).

VENTANA (SOLTI-1501): Oral metronomic vinorelbine combined with endocrine therapy in Eluminal/HER2-negative early breast cancer: A window of opportunity trial

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-OT1-01-04]
Abanell, J., Ciruelos, E., De la Haba, J., Martin, M., Munoz-Molina, B., De Salas-Cansado, M., Colomer, R. (2017).

Cost-effectiveness analysis of adding neoadjuvant chemotherapy with pertuzumab, in patients with HER2+breast cancer in Spain

CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P3-12-02]
Adamo, B, Fidalgo, JAP, Ciruelos, E, Vidal, M, Blanch, S, Lopez, A, Pardo, PG, Murillo, L, Amillano, K, Janez, NM, Gonzalez, X, Canes, J, Prat, A (2017).

VENTANA (SOLTI-1501): Antiproliferative effect of the addition of oral; metronomic vinorelbine to endocrine therapy in luminal/HER2-negative; early breast cancer: A window of opportunity trial

ANNALS OF ONCOLOGY. Meeting Abstract. 28.
Barcena, C, Rojas, K, Lema, L, Sanchez, LM, Rios, J, Garcia-Martin, R, Maroto, A, Rodriguez-Peralto, JL, Gil, EMC, Mendiola, DC, Paz-Ares, L (2017).

Tumor-infiltrating lymphocytes expression in stage IIIc/IV of high-grade; serous ovarian cancer: Variation with neoadjuvant chemotherapy and; prognostic value

ANNALS OF ONCOLOGY. Meeting Abstract. 28.
Deurloo, R, Colombo, N, Mendiola, C, Selle, F, Korach, J, Oestergaard, MZ, Bylesjo, M, Urban, HJ, Ghazi, Y, Oza, A (2017).

Gene mutational analyses in 154 ovarian cancer (OC) samples from the; ROSiA study of front-line bevacizumab (BEV)-containing therapy for OC

ANNALS OF ONCOLOGY. Meeting Abstract. 28.
Di Leo, A, Toi, M, Campone, M, Sohn, J, Paluch-Shimon, S, Huober, J, Park, IH, Tredan, O, Chen, SC, Manso, L, Freedman, O, Jaliffe, GG, Forrester, T, Frenzel, M, Barriga, S, Smith, IC, Bourayou, N, Goetz, MP (2017).

MONARCH 3: Abemaciclib as initial therapy for patients with; HR+/HER2-advanced breast cancer

ANNALS OF ONCOLOGY. Meeting Abstract. 28.
Lopez-Martin, JA, Cala, M, Prieto-Garcia, E, Riano, CG, Diaz-Garcia, CV, Garcia, A, Marques, VP, Pascualena, FR, Garcia-Ruiz, I, Pernaut, C, Otero, I, Rubio, LP, Riesco, MC, Alfonso, JA, Barbas, C, Agullo-Ortuno, MT (2017).

Metabolomics in cancer cachexia

ANNALS OF ONCOLOGY. Meeting Abstract. 28.